Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)

Atezolizumab in combination with nab-paclitaxel has been introduced for the treatment of locally advanced or recurrent triple negative breast cancer (TNBC). Patient selection relies on the use of immunohistochemistry using a specific monoclonal PD-L1 antibody (clone SP142) in a tightly controlled co...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobritoiu, Florin, Baltan, Adelina, Chefani, Alina, Billingham, Kim, Chenard, Marie-Pierrette, Vaziri, Reza, Lacroix-Triki, Magali, Waydelich, Anne, Erb, Gilles, Andersson, Emilia, Cañamero, Marta, Toro, Paula, Wedden, Sarah, D’Arrigo, Corrado
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444286/
https://www.ncbi.nlm.nih.gov/pubmed/36036647
http://dx.doi.org/10.1097/PAI.0000000000001053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444286/
https://www.ncbi.nlm.nih.gov/pubmed/36036647
http://dx.doi.org/10.1097/PAI.0000000000001053

Ejemplares similares